Axsome Therapeutics (AXSM) Competitors $127.94 +2.94 (+2.35%) Closing price 10/17/2025 04:00 PM EasternExtended Trading$130.00 +2.06 (+1.61%) As of 10/17/2025 06:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock AXSM vs. JAZZ, TEVA, GMAB, SMMT, ASND, RDY, VTRS, ROIV, BBIO, and QGENShould you be buying Axsome Therapeutics stock or one of its competitors? The main competitors of Axsome Therapeutics include Jazz Pharmaceuticals (JAZZ), Teva Pharmaceutical Industries (TEVA), Genmab A/S (GMAB), Summit Therapeutics (SMMT), Ascendis Pharma A/S (ASND), Dr. Reddy's Laboratories (RDY), Viatris (VTRS), Roivant Sciences (ROIV), BridgeBio Pharma (BBIO), and Qiagen (QGEN). These companies are all part of the "medical" sector. Axsome Therapeutics vs. Its Competitors Jazz Pharmaceuticals Teva Pharmaceutical Industries Genmab A/S Summit Therapeutics Ascendis Pharma A/S Dr. Reddy's Laboratories Viatris Roivant Sciences BridgeBio Pharma Qiagen Axsome Therapeutics (NASDAQ:AXSM) and Jazz Pharmaceuticals (NASDAQ:JAZZ) are both mid-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, media sentiment, valuation, institutional ownership, profitability and analyst recommendations. Do insiders and institutionals have more ownership in AXSM or JAZZ? 81.5% of Axsome Therapeutics shares are owned by institutional investors. Comparatively, 89.1% of Jazz Pharmaceuticals shares are owned by institutional investors. 22.3% of Axsome Therapeutics shares are owned by insiders. Comparatively, 4.3% of Jazz Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Which has more risk and volatility, AXSM or JAZZ? Axsome Therapeutics has a beta of 0.52, suggesting that its share price is 48% less volatile than the S&P 500. Comparatively, Jazz Pharmaceuticals has a beta of 0.28, suggesting that its share price is 72% less volatile than the S&P 500. Is AXSM or JAZZ more profitable? Jazz Pharmaceuticals has a net margin of -9.91% compared to Axsome Therapeutics' net margin of -49.88%. Jazz Pharmaceuticals' return on equity of 5.02% beat Axsome Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Axsome Therapeutics-49.88% -283.22% -33.06% Jazz Pharmaceuticals -9.91%5.02%1.73% Does the media prefer AXSM or JAZZ? In the previous week, Axsome Therapeutics had 9 more articles in the media than Jazz Pharmaceuticals. MarketBeat recorded 18 mentions for Axsome Therapeutics and 9 mentions for Jazz Pharmaceuticals. Axsome Therapeutics' average media sentiment score of 1.00 beat Jazz Pharmaceuticals' score of 0.98 indicating that Axsome Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Axsome Therapeutics 7 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Jazz Pharmaceuticals 8 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts recommend AXSM or JAZZ? Axsome Therapeutics currently has a consensus target price of $177.93, suggesting a potential upside of 39.08%. Jazz Pharmaceuticals has a consensus target price of $178.93, suggesting a potential upside of 31.51%. Given Axsome Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Axsome Therapeutics is more favorable than Jazz Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Axsome Therapeutics 1 Sell rating(s) 0 Hold rating(s) 14 Buy rating(s) 2 Strong Buy rating(s) 3.00Jazz Pharmaceuticals 1 Sell rating(s) 2 Hold rating(s) 14 Buy rating(s) 0 Strong Buy rating(s) 2.76 Which has higher earnings and valuation, AXSM or JAZZ? Jazz Pharmaceuticals has higher revenue and earnings than Axsome Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Jazz Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAxsome Therapeutics$495.03M12.90-$287.22M-$5.07-25.23Jazz Pharmaceuticals$4.07B2.03$560.12M-$6.73-20.22 SummaryAxsome Therapeutics beats Jazz Pharmaceuticals on 9 of the 16 factors compared between the two stocks. Get Axsome Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AXSM and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AXSM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AXSM vs. The Competition Export to ExcelMetricAxsome TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.38B$3.44B$6.21B$10.54BDividend YieldN/A2.28%5.70%4.80%P/E Ratio-25.2323.1685.7027.13Price / Sales12.90449.16581.70177.21Price / CashN/A46.9237.1060.81Price / Book108.4210.4112.236.52Net Income-$287.22M-$52.77M$3.33B$276.93M7 Day Performance5.12%2.31%1.17%1.93%1 Month Performance10.34%12.59%6.85%2.19%1 Year Performance37.05%11.18%58.93%34.62% Axsome Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AXSMAxsome Therapeutics4.7333 of 5 stars$127.94+2.4%$177.93+39.1%+37.1%$6.38B$495.03M-25.23380Positive NewsAnalyst RevisionJAZZJazz Pharmaceuticals4.5661 of 5 stars$135.14-0.2%$178.93+32.4%+18.3%$8.20B$4.07B-20.082,800TEVATeva Pharmaceutical Industries3.5875 of 5 stars$20.02-0.1%$25.57+27.8%+7.7%$22.96B$16.63B-125.0936,830GMABGenmab A/S3.6417 of 5 stars$32.68+2.7%$40.80+24.8%+44.3%$20.98B$3.26B16.422,682Trending NewsAnalyst ForecastShort Interest ↑Analyst RevisionSMMTSummit Therapeutics3.006 of 5 stars$22.93+7.4%$31.29+36.4%-1.0%$17.03B$700K-22.70110News CoverageUpcoming EarningsGap DownASNDAscendis Pharma A/S2.836 of 5 stars$208.43-0.5%$248.29+19.1%+62.0%$12.86B$393.54M-40.391,017News CoverageAnalyst UpgradeAnalyst RevisionRDYDr. Reddy's Laboratories3.0671 of 5 stars$14.36+0.1%$16.95+18.1%-9.4%$11.99B$3.81B21.7527,811Positive NewsVTRSViatris3.0567 of 5 stars$9.86+1.2%$10.40+5.5%-13.5%$11.50B$14.12B-3.4032,000News CoverageAnalyst ForecastROIVRoivant Sciences2.9516 of 5 stars$16.21+1.1%$19.94+23.0%+44.8%$11.07B$29.05M-23.16860Insider TradeBBIOBridgeBio Pharma4.4987 of 5 stars$55.96+0.8%$63.94+14.3%+111.1%$10.70B$235.81M-13.68400Positive NewsAnalyst RevisionQGENQiagen4.136 of 5 stars$47.30+1.0%$49.40+4.4%+15.5%$10.51B$2.04B27.955,765News CoveragePositive News Related Companies and Tools Related Companies JAZZ Alternatives TEVA Alternatives GMAB Alternatives SMMT Alternatives ASND Alternatives RDY Alternatives VTRS Alternatives ROIV Alternatives BBIO Alternatives QGEN Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AXSM) was last updated on 10/19/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredTrump’s new nightmare beginsPorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | Sponsored$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredBuy alert: Move $1,000 before Tesla’s Optimus launchElon's $1,000,000,000,000 payday Elon Musk just made his biggest insider purchase of Tesla stock ever. He's...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Axsome Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Axsome Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
